|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/14/18 Biolase, Inc 10-Q 9/30/18 81:11M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: 10-Q 10-Q Q3 2018 HTML 703K
2: EX-4.1 Instrument Defining the Rights of Security Holders HTML 70K
3: EX-4.2 Instrument Defining the Rights of Security Holders HTML 132K
4: EX-10.3 Material Contract HTML 97K
5: EX-10.4 Material Contract HTML 85K
6: EX-10.5 Material Contract HTML 64K
7: EX-10.6 Material Contract HTML 921K
8: EX-31.1 Certification -- §302 - SOA'02 HTML 30K
9: EX-31.2 Certification -- §302 - SOA'02 HTML 30K
10: EX-32.1 Certification -- §906 - SOA'02 HTML 24K
11: EX-32.2 Certification -- §906 - SOA'02 HTML 25K
18: R1 Document and Entity Information HTML 47K
19: R2 Consolidated Balance Sheets (Unaudited) HTML 117K
20: R3 Consolidated Balance Sheets (Unaudited) HTML 45K
(Parenthetical)
21: R4 Consolidated Statements Of Operations And HTML 103K
Comprehensive Loss (Unaudited)
22: R5 Consolidated Statements Of Cash Flows (Unaudited) HTML 128K
23: R6 Description of Business and Basis of Presentation HTML 39K
24: R7 Summary of Significant Accounting Policies HTML 40K
25: R8 Revenue Recognition HTML 201K
26: R9 Stockholders' Equity HTML 305K
27: R10 Inventory HTML 42K
28: R11 Property, Plant, and Equipment HTML 60K
29: R12 Intangible Assets and Goodwill HTML 27K
30: R13 Accrued Liabilities HTML 104K
31: R14 Lines of Credit HTML 35K
32: R15 Commitments and Contingencies HTML 49K
33: R16 Segment Information HTML 69K
34: R17 Concentrations HTML 102K
35: R18 Income Taxes HTML 34K
36: R19 Subsequent Event HTML 29K
37: R20 Summary of Significant Accounting Policies HTML 75K
(Policies)
38: R21 Revenue Recognition (Tables) HTML 192K
39: R22 Stockholders' Equity (Tables) HTML 300K
40: R23 Inventory (Tables) HTML 43K
41: R24 Property, Plant, and Equipment (Tables) HTML 60K
42: R25 Accrued Liabilities (Tables) HTML 105K
43: R26 Commitments and Contingencies (Tables) HTML 36K
44: R27 Segment Information (Tables) HTML 70K
45: R28 Concentrations (Tables) HTML 102K
46: R29 Description of Business and Basis of Presentation HTML 68K
- Additional Information (Detail)
47: R30 Revenue Recognition - Additional Information HTML 36K
(Detail)
48: R31 Summary of Opening and Closing Balances of HTML 42K
Contract Liabilities (Detail)
49: R32 Summary of Disaggregation of Revenues Related to HTML 31K
Geographic Areas (Detail)
50: R33 Summary of Revenues Disaggregated by Timing of HTML 32K
Goods and Services Transferred (Detail)
51: R34 Summary of Sales by End Market (Detail) HTML 32K
52: R35 Summary of Percentages of Sales by Product line HTML 39K
(Detail)
53: R36 Stockholders' Equity - Additional Information HTML 213K
(Detail)
54: R37 Classification of Compensation Expense Associated HTML 37K
with Share-Based Payments (Detail)
55: R38 Assumptions Used in Estimating Fair Value of Stock HTML 32K
Options Granted (Detail)
56: R39 Summary of Option Activity (Detail) HTML 70K
57: R40 Summary of Unvested Stock Option Activity (Detail) HTML 46K
58: R41 Cash Proceeds Along with Fair Value Disclosures HTML 35K
Related to Grants, Exercises and Vested Options
(Detail)
59: R42 Summary of Unvested Restricted Stock Units HTML 49K
(Detail)
60: R43 Summary of Warrant Activity (Detail) HTML 46K
61: R44 Components of Inventory (Detail) HTML 33K
62: R45 Inventory - Additional Information (Detail) HTML 26K
63: R46 Summary of Property, Plant, and Equipment (Detail) HTML 47K
64: R47 Property, Plant, and Equipment - Additional HTML 26K
Information (Detail)
65: R48 Intangible Assets and Goodwill - Additional HTML 32K
Information (Detail)
66: R49 Components of Accrued Liabilities (Detail) HTML 45K
67: R50 Changes in Initial Product Warranty Accrual and HTML 40K
Expenses Under Initial and Extended Warranties
(Detail)
68: R51 Accrued Liabilities - Additional Information HTML 28K
(Detail)
69: R52 Lines of Credit - Additional Information (Detail) HTML 123K
70: R53 Commitments and Contingencies - Additional HTML 57K
Information (Detail)
71: R54 Future Minimum Rental Commitments Under Lease HTML 32K
Agreements (Detail)
72: R55 Segment Information - Additional Information HTML 37K
(Detail)
73: R56 Summary of Net Revenue by Geographic Location HTML 31K
(Detail)
74: R57 Summary of Property, Plant and Equipment by HTML 31K
Geographic Location (Detail)
75: R58 Concentrations - Summary of Net Revenue from HTML 52K
Various Products (Detail)
76: R59 Concentrations - Additional Information (Detail) HTML 39K
77: R60 Income Taxes - Additional Information (Detail) HTML 36K
78: R61 Subsequent Event - Additional Information (Detail) HTML 76K
80: XML IDEA XML File -- Filing Summary XML 135K
79: EXCEL IDEA Workbook of Financial Reports XLSX 83K
12: EX-101.INS XBRL Instance -- biol-20180930 XML 2.41M
14: EX-101.CAL XBRL Calculations -- biol-20180930_cal XML 151K
15: EX-101.DEF XBRL Definitions -- biol-20180930_def XML 488K
16: EX-101.LAB XBRL Labels -- biol-20180930_lab XML 1.13M
17: EX-101.PRE XBRL Presentations -- biol-20180930_pre XML 888K
13: EX-101.SCH XBRL Schema -- biol-20180930 XSD 184K
81: ZIP XBRL Zipped Folder -- 0001564590-18-029550-xbrl Zip 158K
Exhibit 4.1
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), AND MAY NOT BE SOLD, PLEDGED, OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR PURSUANT TO RULE 144 OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY AND ITS COUNSEL, THAT SUCH REGISTRATION IS NOT REQUIRED.
WARRANT TO PURCHASE STOCK
Issuer: BIOLASE, INC., a Delaware corporation (the “Company”)
Number of Shares: the number of fully paid and non-assessable shares (after taking into account adjustments made pursuant to stock splits, reverse stock splits and other events specified in Article 2) of Common Stock obtained by dividing (i) $120,000, by (ii) the applicable Exercise Price at the time this Warrant is exercised.
Class of Stock: Common Stock
Exercise Price per Share: $2.13 (as may be adjusted in accordance with Article 2)
Issue Date: September 27, 2018
Expiration Date: September 27, 2028
THIS WARRANT CERTIFIES THAT, for the agreed upon value of $1.00 and for other good and valuable consideration, WESTERN ALLIANCE BANK, or its assignees (“Holder”) is entitled to purchase the number of fully paid and nonassessable shares of the Company’s capital stock set forth above (the “Shares”) at the Exercise Price per Share set forth above, as the same may be from time to time adjusted pursuant to Article 2 hereof and subject to the provisions and upon the terms and conditions set forth in this Warrant.
Article 1eXERCISE.
1.1Method of Exercise. This Warrant is exercisable, in whole or in part, at any time and from time to time on or before the Expiration Date set forth above. Holder may exercise this Warrant by delivering a duly executed Notice of Exercise, in substantially the form attached hereto as Appendix 1, to the principal office of Company. Unless Holder is exercising the conversion right set forth in Section 1.2, Holder shall also deliver to Company an amount equal to the aggregate Exercise Price for Shares being purchased, by check or wire.
1.2Conversion Right. In lieu of exercising this Warrant as specified in Section 1.1, Holder may from time to time convert this Warrant, in whole or in part, into a number of Shares determined by dividing (a) the aggregate fair market value of Shares or other securities otherwise issuable upon exercise of this Warrant minus the aggregate Exercise Price of such Shares by (b) the fair market value of one Share. The fair market value of Shares shall be determined pursuant to Section 1.3.
|
1865633.1 |
1 |
1.3Fair Market Value. If the Shares are traded in a public market, the fair market value of the Shares shall be the closing price of the Shares (or the closing price of the Company’s stock into which the Shares are convertible) reported for the business day immediately before Holder delivers its Notice of Exercise to the Company. If the Shares are not traded in a public market, the Board of Directors of Company shall determine fair market value in its reasonable good faith judgment. The foregoing notwithstanding, if Holder advises the Board of Directors in writing that Holder disagrees with such determination, then Company and Holder shall promptly agree upon a reputable investment banking firm to undertake such valuation. If the valuation of such investment banking firm is greater than that determined by the Board of Directors, then all fees and expenses of such investment banking firm shall be paid by Company. In all other circumstances, such fees and expenses of such investment banking firm shall be paid by Holder.
1.4Delivery of Certificate and New Warrant. Promptly (and in no event more than 3 business days after exercise) after Holder exercises or converts this Warrant, Company shall deliver to Holder certificates for Shares acquired and, if this Warrant has not been fully exercised or converted and has not expired, a new Warrant representing Shares not yet acquired.
1.5Replacement of Warrant. On receipt of evidence reasonably satisfactory to Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form and amount to Company or, in the case of mutilation, on surrender and cancellation of this Warrant, Company at its expense shall execute and deliver a replacement Warrant.
1.6Sale, Merger, or Consolidation of Company. For the purpose of this Warrant, “Acquisition” means any sale, license, or other disposition of all or substantially all of the assets of Company, or any reorganization, consolidation, or merger of Company where the holders of Company’s securities before the transaction beneficially own less than 50% of the outstanding voting securities of the surviving entity after the transaction. Upon the closing of any Acquisition, the successor entity shall assume the obligations of this Warrant, and this Warrant shall be exercisable for the same securities, cash, and property as would be payable for Shares issuable upon exercise of the unexercised portion of this Warrant as if such Shares were outstanding on the record date for the Acquisition and subsequent closing, and the Exercise Price shall be adjusted accordingly; provided that if pursuant to such Acquisition the entire outstanding class of Shares issuable upon exercise of the unexercised portion of this Warrant are cancelled and the total consideration payable to the holders of such class of Shares consists entirely of cash, then, upon payment to the holder of this Warrant of an amount equal to the amount such holder would receive if such holder held Shares issuable upon exercise of the unexercised portion of this Warrant and such Shares were outstanding on the record date for the Acquisition less the aggregate Exercise Price of such Shares, this Warrant shall be cancelled.
1.7Automatic Cashless Exercise upon Expiration. In the event that, upon the Expiration Date or other termination of the warrant, the fair market value of one Share (or other security issuable upon the exercise hereof) as determined in accordance with Section 1.3 above is greater than the Exercise Price in effect on such date, then this Warrant shall automatically be deemed on and as of such date to be exercised pursuant to Section 1.2 above as to all Shares (or such other securities) for which it shall not previously have been exercised, and the Company shall, within a reasonable time, deliver a certificate representing the Shares (or such other securities) issued upon such exercise to Holder.
|
1865633.1 |
2 |
2.1Stock Dividends, Splits, Etc. If Company declares or pays a dividend on its common stock (or Shares, if Shares are securities other than common stock) payable in common stock or other securities or property, subdivides the outstanding common stock into a greater amount of common stock, or, if Shares are securities other than common stock, subdivides Shares in a transaction that increases the amount of common stock into which Shares are convertible, then upon exercise of this Warrant, for each Share acquired, Holder shall receive, without cost to Holder, the total number and kind of securities to which Holder would have been entitled had Holder owned Shares on the record date the dividend or subdivision occurred since the original issue date of this Warrant.
2.2Reclassification, Recapitalization, Exchange or Substitution. Upon any reclassification, recapitalization, exchange, substitution, or other event that results in a change of the number and/or class of the securities issuable upon exercise or conversion of this Warrant, Holder shall be entitled to receive, upon exercise or conversion of this Warrant, the number and kind of securities and property that Holder would have received for Shares if this Warrant had been exercised immediately before such reclassification, recapitalization, exchange, substitution, or other event. Company or its successor shall promptly issue to Holder a new Warrant for such new securities or other property. The new Warrant shall provide for adjustments which shall be as nearly equivalent as may be practicable to the adjustments provided for in this Article 2 including, without limitation, adjustments to the Exercise Price and to the number of securities or property issuable upon exercise of the new Warrant. The provisions of this Section 2.2 shall similarly apply to successive reclassifications, recapitalizations, exchanges, substitutions, or other events.
2.3Adjustments for Combinations, Etc. If the outstanding Shares are combined or consolidated, by reclassification or otherwise, into a lesser number of shares, the Exercise Price shall be proportionately increased and the number of Shares as to which this warrant is exercisable shall be proportionately decreased.
2.4Adjustments for Diluting Issuances. In the event of the issuance (a “Diluting Issuance”) by Company, after the Issue Date of the Warrant, of any Additional Shares of Common Stock (as defined in the Company’s Certificate of Incorporation) at a price per share less than the then Exercise Price, then the number of shares of common stock issuable upon conversion of the Shares, and the conversion price, shall be adjusted in accordance with those provisions (the “Provisions”) of Company’s Certificate of Incorporation which apply to Diluting Issuances with the same effect as though the shares were outstanding at the time of the diluting issuance. Company agrees that the Provisions, as in effect on the Issue Date, shall be deemed to remain in full force and effect during the term of the Warrant notwithstanding any subsequent amendment, waiver or termination thereof by Company’s shareholders. Under no circumstances shall the aggregate Exercise Price payable by Holder upon exercise of the Warrant increase as a result of any adjustment arising from a Diluting Issuance.
2.5Reserved.
2.6No Impairment. Company shall not, by amendment of its Certificate of Incorporation or through a reorganization, transfer of assets, consolidation, merger, dissolution, issue, or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed under this Warrant by Company, but shall at all times
|
1865633.1 |
3 |
in good faith assist in carrying out of all the provisions of this Article 2 and in taking all such action as may be necessary or appropriate to protect Holder’s rights under this Article against impairment. If Company takes any action affecting Shares or its common stock as described above that adversely affects Holder’s rights under this Warrant, the Exercise Price shall be adjusted downward and the number of Shares issuable upon exercise of this Warrant shall be adjusted upward in such a manner that such action is offset and the aggregate Exercise Price of this Warrant is unchanged.
2.7Fractional Shares. No fractional Shares shall be issuable upon exercise or conversion of the Warrant and the number of Shares to be issued shall be rounded down to the nearest whole Share. If a fractional share interest arises upon any exercise or conversion of the Warrant, Company shall eliminate such fractional share interest by paying Holder an amount computed by multiplying the fractional interest by the fair market value of a full Share.
2.8Certificate as to Adjustments. Upon each adjustment of the Exercise Price, Company at its expense shall promptly compute such adjustment, and furnish Holder with a certificate of its Chief Financial Officer setting forth the Exercise Price in effect upon the date thereof and the series of adjustments leading to such Exercise Price, and the facts upon which such adjustment is based.
Article 3REPRESENTATIONS, WARRANTIES AND COVENANTS OF COMPANY.
3.1Representations and Warranties. The Company hereby represents and warrants to Holder as follows:
(a)The initial Exercise Price referenced on the first page of this Warrant is not greater than the fair market value of the Shares as of the date of this Warrant.
(b)As of the date hereof, the Company has sufficient authorized shares reserved for the issuance of all capital stock which may be issued upon the exercise of this Warrant.
(c)The Company’s capitalization table attached to this Warrant as Appendix 2 is true and complete as of the Issue Date.
3.2Valid Issuance. Company shall take all steps necessary to insure that all Shares which may be issued upon the exercise of this Warrant, and all securities, if any, issuable upon conversion of Shares, shall, upon issuance, be duly authorized, validly issued, fully paid and nonassessable, and free of any liens and encumbrances except for restrictions on transfer provided for herein or under applicable federal and state securities laws.
3.3Notice of Certain Events. If Company proposes at any time (a) to declare any dividend or distribution upon its common stock, whether in cash, property, stock, or other securities and whether or not a regular cash dividend; (b) to offer for subscription pro rata to the holders of any class or series of its stock any additional shares of stock of any class or series or other rights; (c) to effect any reclassification or recapitalization of common stock; (d) to merge or consolidate with or into any other corporation, or sell, lease, license, or convey all or substantially all of its assets, or to liquidate, dissolve or wind up; or (e) offer holders of registration rights the opportunity to participate in an underwritten public offering of the company’s securities for cash, then, in connection with each such event, Company shall give Holder (1) in the case of the matters referred to in (a) and (b) above at least 20 days prior written notice of the date on which a record will be taken for such dividend, distribution, or subscription rights (and specifying the date on which the holders of common stock will be entitled thereto) or for determining rights to vote, if any, in respect
|
1865633.1 |
4 |
of the matters referred to in (c) and (d) above; (2) in the case of the matters referred to in (c) and (d) above at least 20 days prior written notice of the date when the same will take place (and specifying the date on which the holders of common stock will be entitled to exchange their common stock for securities or other property deliverable upon the occurrence of such event); and (3) in the case of the matter referred to in (e) above, the same notice as is given to the holders of such registration rights.
3.4(a)Information. So long as Holder holds this Warrant and/or any of the Shares, Company shall deliver to Holder (i) promptly, copies of all notices or other written communications to which Holder would be entitled if it held Shares as to which this Warrant was then exercisable and (ii) such other financial statements required under and in accordance with any loan documents between Holder and Company, or if there are no such requirements or if the subject loan(s) are no longer are outstanding, then within 45 days after the end of each of the first three quarters of each fiscal year, Company’s quarterly, unaudited financial statements and within 90 days after the end of each fiscal year, Company’s annual, audited financial statements.
(b)Exempt Transaction. The issuance of the Shares will each constitute a transaction exempt from (i) the registration requirements of Section 5 of the Act, in reliance upon Section 4(2) thereof and/or Regulation D thereunder, and (ii) the qualification requirements of applicable state securities laws.
(c)Compliance with Rule 144. If Holder proposes to sell the Shares issuable upon the exercise of this Warrant in compliance with Rule 144 promulgated by the SEC, then, upon Holder’s written request to the Company, the Company shall furnish to Holder, within ten days after receipt of such request, a written statement confirming the Company’s compliance with the filing requirements of the SEC as set forth in such rule (as may be amended from time to time).
3.5Reserved.
Article 4Representations and Warranties of Holder.
Holder represents and warrants to the Company as follows:
4.1Purchase for Own Account. This Warrant and the Shares to be acquired upon exercise of this Warrant by Holder are being acquired for investment for Holder’s account, not as a nominee or agent, and not with a view to the public resale or distribution within the meaning of the Act. Holder also represents that it has not been formed for the specific purpose of acquiring this Warrant or the Shares.
4.2Disclosure of Information. Holder is aware of the Company’s business affairs and financial condition and has received or has had full access to all the information it considers necessary or appropriate to make an informed investment decision with respect to the acquisition of this Warrant and its underlying securities. Holder further has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities and to obtain additional information (to the extent the Company possessed such information or could acquire it without unreasonable effort or expense) necessary to verify any information furnished to Holder or to which Holder has access.
4.3Investment Experience. Holder understands that the purchase of this Warrant and its underlying securities involves substantial risk. Holder has experience as an investor in securities of companies in the development stage and acknowledges that Holder can bear the economic risk
|
1865633.1 |
5 |
of such Holder’s investment in this Warrant and its underlying securities and has such knowledge and experience in financial or business matters that Holder is capable of evaluating the merits and risks of its investment in this Warrant and its underlying securities and/or has a preexisting personal or business relationship with the Company and certain of its officers, directors or controlling persons of a nature and duration that enables Holder to be aware of the character, business acumen and financial circumstances of such persons.
4.4Accredited Investor Status. Holder is an “accredited investor” within the meaning of Regulation D promulgated under the Act.
4.5The Act. Holder understands that this Warrant and the Shares issuable upon exercise hereof have not been registered under the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of Holder’s investment intent as expressed herein. Holder understands that this Warrant and the Shares issued upon any exercise hereof must be held indefinitely unless subsequently registered under the Act and qualified under applicable state securities laws, or unless exemption from such registration and qualification are otherwise available. Holder is aware of the provisions of Rule 144 promulgated under the Act.
4.6No Voting Rights. Holder, as a Holder of this Warrant, will not have any voting rights until the exercise of this Warrant.
Article 5MISCELLANEOUS.
5.1Legends. This Warrant and the Shares (and the securities issuable, directly or indirectly, upon conversion of Shares, if any) shall be imprinted with a legend in substantially the following form:
THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR PURSUANT TO RULE 144 OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO COMPANY AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED.
5.2Compliance with Securities Laws on Transfer. This Warrant and the Shares issuable upon exercise of this Warrant (and the securities issuable, directly or indirectly, upon conversion of Shares, if any) may not be transferred or assigned in whole or in part without compliance with applicable federal and state securities laws by the transferor and the transferee (including, without limitation, the delivery of investment representation letters and legal opinions reasonably satisfactory to Company, as reasonably requested by Company). Company shall not require Holder to provide an opinion of counsel if the transfer is to Holder’s parent company, Western Alliance Bancorporation, or any other affiliate of Holder, or if there is no material question as to the availability of current information as referenced in Rule 144(c), Holder represents that it has complied with Rule 144(d) and (e) in reasonable detail, the selling broker represents that it has complied with Rule 144(f), and the Company is provided with a copy of Holder’s notice of proposed sale.
5.3Transfer Procedure. After receipt by Holder of the executed Warrant, Holder may transfer all of this Warrant to Holder’s parent company, Western Alliance Bancorporation, or an affiliate thereof or successor thereto (the “Subsequent Holder”), by execution of an Assignment
|
1865633.1 |
6 |
substantially in the form of Appendix 3. Subject to the provisions of Article 4.2 and upon providing Company with written notice, the Subsequent Holder may transfer all or part of this Warrant or the Shares issuable upon exercise of this Warrant (or the Shares issuable directly or indirectly, upon conversion of the Shares, if any) to any transferee, provided, however, in connection with any such transfer, the Subsequent Holder will give the Company notice of the portion of the Warrant being transferred with the name, address and taxpayer identification number of the transferee and Holder will surrender this Warrant to the Company for reissuance to the transferee(s) (and Holder if applicable).
5.4Notices. All notices and other communications from Company to Holder, or vice versa, shall be in writing and shall be deemed delivered and effective when given personally or mailed by first‑class registered or certified mail, postage prepaid, or by overnight courier, at such address as may have been furnished to Company or Holder, as the case may be, in writing by Company or such Holder from time to time.
5.5Attorneys’ Fees. In the event of any dispute between the parties concerning the terms and provisions of this Warrant, the party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys’ fees.
5.6Governing Law. This Warrant shall be governed by and construed in accordance with the laws of the State of Arizona, without giving effect to its principles regarding conflicts of law.
[SIGNATURE PAGE FOLLOWS]
|
1865633.1 |
7 |
IN WITNESS WHEREOF, the undersigned has executed this Warrant as of the day and year first above written.
|
COMPANY: |
||
|
|
||
|
BIOLASE, INC., a Delaware corporation |
||
|
|
|
|
|
By: |
|
/s/ JOHN R. BEAVER |
|
Name: |
|
|
|
Title: |
|
Executive Vice President and Chief Financial Officer |
|
1865633.1 |
8 |
NOTICE OF EXERCISE
[Strike paragraph that does not apply.]
1.The undersigned hereby elects to purchase shares of the Common Stock of Company pursuant to the terms of the attached Warrant, and tenders herewith payment of the purchase price of such shares in full.
1. The undersigned hereby elects to convert the attached Warrant into Shares/cash [strike one] in the manner specified in the Warrant. This conversion is exercised with respect to _____________________ of the Shares covered by the Warrant.
2.Please issue a certificate or certificates representing said shares in the name of the undersigned or in such other name as is specified below:
|
Name: |
|
|
|
Address: |
|
|
|
|
|
|
3.The undersigned represents it is acquiring the shares solely for its own account and not as a nominee for any other party and not with a view toward the resale or distribution thereof except in compliance with applicable securities laws.
|
WESTERN ALLIANCE BANK, an Arizona corporation |
||
|
|
|
|
|
By: |
|
|
|
Name: |
|
|
|
Title: |
|
|
|
|
|
|
|
1865633.1 |
1 |
CAPITALIZATION TABLE
|
1865633.1 |
1 |
ASSIGNMENT
For value received, WESTERN ALLIANCE BANK, hereby sells, assigns and transfers unto:
|
Name: |
|
WESTERN ALLIANCE BANCORPORATION |
|
Address: |
|
One E. Washington, Suite 1400 |
|
|
|
|
|
|
|
Tax ID: |
that certain Warrant to Purchase Stock issued by BIOLASE, INC., a Delaware corporation (the “Company”), on September __, 2018 (the “Warrant”) together with all rights, title and interest therein.
|
WESTERN ALLIANCE BANK |
||
|
|
|
|
|
By: |
|
|
|
Name: |
|
|
|
Title: |
|
|
|
|
|
|
By its execution below, and for the benefit of the Company, Western Alliance Bancorporation agrees to all other provisions of the Warrant as of the date hereof.
|
WESTERN ALLIANCE BANCORPORATION |
||
|
|
|
|
|
By: |
|
|
|
Name: |
|
|
|
Title: |
|
|
|
|
|
|
|
1865633.1 |
2 |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 9/27/28 | ||||
| Filed on: | 11/14/18 | |||
| For Period end: | 9/30/18 | |||
| 9/27/18 | 8-K | |||
| List all Filings | ||||